VC
XERS icon

Veery Capital’s Xeris Biopharma Holdings XERS Stock Holding History

Veery Capital’s Portfolio XERS Stock Details XERS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-14,163
Closed -$115K – 99
2025
Q3 		$115K Hold
14,163
– – 0.04% 94
2025
Q2 		$66.1K Hold
14,163
– – 0.02% 94
2025
Q1 		$77.8K Hold
14,163
– – 0.03% 92
2024
Q4 		$48K Hold
14,163
– – 0.02% 91
2024
Q3 		$40.4K Hold
14,163
– – 0.02% 94
2024
Q2 		$31.9K Hold
14,163
– – 0.01% 96
2024
Q1 		$31.3K Buy
14,163
+1,619
+13% +$4.19K 0.01% 96
2023
Q4 		$29.5K Hold
12,544
– – 0.01% 90
2023
Q3 		$23.3K Hold
12,544
– – 0.01% 81
2023
Q2 		$32.9K Hold
12,544
– – 0.02% 85
2023
Q1 		$20.4K Hold
12,544
– – 0.01% 82
2022
Q4 		$16.7K Hold
12,544
– – 0.01% 71
2022
Q3 		$20K Hold
12,544
– – 0.01% 71
2022
Q2 		$19K Buy
+12,544
New +$26.5K 0.01% 73
2022
Q1 		– Sell
-12,544
Closed -$37K – 86
2021
Q4 		$37K Buy
+12,544
New +$27.1K 0.02% 81

Other funds holding XERS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Veery Capital's XERS Position: Q4 2025 in Review

Veery Capital sold out of Xeris Biopharma Holdings (XERS) in Q4 2025, closing a stake of 14,163 shares — an estimated $115K sold.

Veery Capital first reported a position in XERS in Q4 2021 and held it in 15 quarters. The position peaked at $115K in Q3 2025. 225 funds tracked by Wall St. Rank hold XERS as of Q4 2025.

  • Veery Capital reported no remaining Xeris Biopharma Holdings position as of Q4 2025 after selling out during the quarter.
  • Veery Capital sold 14,163 Xeris Biopharma Holdings shares in Q4 2025, an estimated $115K.
  • Veery Capital first reported a position in Xeris Biopharma Holdings in Q4 2021 and held it in 15 quarters.
  • Veery Capital's Xeris Biopharma Holdings position peaked at $115K in Q3 2025.
  • 225 funds tracked by Wall St. Rank held Xeris Biopharma Holdings as of Q4 2025.

Based on Veery Capital's 13F filing for Q4 2025, filed 27 Jan 2026.